“Tages Shaw” stated on its Instagram page that the “Biontech” company, which is based in Mainz, Germany, is conducting a joint test with its South American partners, the American “Pfizer”. And this is against the backdrop of the dramatic increase in the number of injuries in Brazil in recent months.
The researchers hope to get positive results faster, and they also seek to find out whether vaccines may help protect people at risk of infection more than others, such as bus drivers or transportation, given that they are subject to these tests more than others, because they are in constant and daily contact. With people, according to the same source.
And the West German public broadcaster SWR reported on Thursday evening (October 29) that Ugur Shaheen, Chairman of the Board of Directors of Biontech, had stated in an interview with the newspapers of the “VRM” group that the current clinical tests carried positive results, and that in case of confirmation (that) Success), the authorization to market the drug will soon be obtained.
According to what was transferred, the site could happen before the end of this year. Shaheen expects more initial results within two weeks, referring to the first data on vaccine tolerance, which he expects in mid-November.
On the basis of these results, European authorities can issue the so-called emergency approval of Biontech, as well as other vaccine developers, according to the “SWR” website.
Ugur Shaheen, 55, chairman of the board of directors of German Biontech in Mainz, which is developing a vaccine against Corona
And she was Health authorities in Brazil Last week, it announced the death of a Brazilian volunteer who participated in clinical trials of vaccines against Corona, according to what was published by the French newspaper “Les Echos”.
However, the French newspaper quoted Brazilian sources as saying that the deceased woman during the clinical trial had not received the vaccine dose yet, and it is likely that the causes of death are related to complications from her infection with the virus.
It is reported that the Ministry of Health in Brazil announced on Wednesday (October 28, 2020) that the country has registered 510 New deaths due to Corona, In addition to 28,629 new cases of the virus among the citizens.
In all, Brazil has recorded about 5.5 million cases of the virus and more than 158,000 deaths. According to these figures, Brazil is the second country with the largest number of deaths due to the virus in the world, followed by the United States, which ranks first.
MB / P.C.
-
Waning immune response is the biggest obstacle to developing a Corona vaccine
‘Fade away quickly’
Initial studies conducted in China, Germany, Britain and other countries concluded that patients infected with the emerging coronavirus develop protective antivirus bodies as part of the body’s immune system, but it seems that these bodies only remain effective for only a few months. Daniel Altman, professor of immunology from Imperial College London, said that “their effect (self-developed protective bodies) often wanes rapidly.”
-
Waning immune response is the biggest obstacle to developing a Corona vaccine
Two options for vaccine developers
Experts say that the rapid weakness of immunity raises major problems for vaccine developers, and for public health authorities as well as those seeking to spread these vaccines to protect their people from future epidemics. “For vaccines to be really effective, there are two options: either the need to develop more robust and longer-term protection … or the vaccine should be obtained regularly,” said Stephen Griffin, assistant professor of medicine at the University of Leeds.
-
Waning immune response is the biggest obstacle to developing a Corona vaccine
World race
More than 100 companies and research teams are seeking to develop vaccines, of which at least 17 are currently being tried in humans. The American company Moderna announced Tuesday (July 15, 2020) that the clinical trials will enter the final stage on July 27. Moderna is thus the first company to reach this stage. Russia announced that it had completed the first clinical trials of an experimental human-tested vaccine, to be fully completed by the end of July.
-
Waning immune response is the biggest obstacle to developing a Corona vaccine
Two doses are “better” than one
In preclinical trials on pigs to monitor the effect of a vaccine developed by the pharmaceutical company (AstraZeneca) to treat Covid-19, known as (AZD 1222), it was found that two doses of the vaccine contributed to the antibody response better than one dose. However, so far, there is no data recorded in any human vaccine trials to show whether any immune response to the antibody will be strong or long-lasting enough.
-
Waning immune response is the biggest obstacle to developing a Corona vaccine
Time pressure
Geoffrey Arnold, a visiting professor of microbiology at the University of Oxford in Britain and a former expert at Sanofi Pasteur, said that the development and very rapid testing of potential vaccines against the Corona virus have been taking place for only six months, which is not long enough to show how long the vaccines might provide. Experts expect that it will take 12-18 months to produce a safe and effective vaccine from the start of development.
-
Waning immune response is the biggest obstacle to developing a Corona vaccine
Booster doses
One approach, Griffin-Arnold said, might be that when those vaccines are being developed, authorities should consider getting booster doses for millions of people at regular intervals or even combining two or more vaccines for each person to get the best protection possible. However, this may represent a major challenge on a practical level. “Giving the whole world one dose of the vaccine is one thing … and giving them multiple doses is another thing entirely,” he said.
These were the details of the news Is it close to authorizing the use of a German vaccine... for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.
It is also worth noting that the original news has been published and is available at saudi24news and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.
